KR20070115580A - 클로스트리디움 박테리아를 위한 배지 및 클로스트리디움계독소를 얻기 위한 프로세스 - Google Patents

클로스트리디움 박테리아를 위한 배지 및 클로스트리디움계독소를 얻기 위한 프로세스 Download PDF

Info

Publication number
KR20070115580A
KR20070115580A KR1020067017946A KR20067017946A KR20070115580A KR 20070115580 A KR20070115580 A KR 20070115580A KR 1020067017946 A KR1020067017946 A KR 1020067017946A KR 20067017946 A KR20067017946 A KR 20067017946A KR 20070115580 A KR20070115580 A KR 20070115580A
Authority
KR
South Korea
Prior art keywords
medium
botulinum toxin
fermentation
animal
botulinum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067017946A
Other languages
English (en)
Korean (ko)
Inventor
핑 왕
스테픈 도노반
Original Assignee
알러간, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35219398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20070115580(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알러간, 인코포레이티드 filed Critical 알러간, 인코포레이티드
Priority claimed from US11/072,050 external-priority patent/US7160699B2/en
Publication of KR20070115580A publication Critical patent/KR20070115580A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020067017946A 2005-03-03 2005-03-03 클로스트리디움 박테리아를 위한 배지 및 클로스트리디움계독소를 얻기 위한 프로세스 Ceased KR20070115580A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/072,673 2005-03-03
US11/072,050 US7160699B2 (en) 2003-09-25 2005-03-03 Media for clostridium bacterium and processes for obtaining a clostridial toxin
US11/072,673 US7354740B2 (en) 2003-09-25 2005-03-03 Animal product free system and process for purifying a botulinum toxin
US11/072,050 2005-03-03

Publications (1)

Publication Number Publication Date
KR20070115580A true KR20070115580A (ko) 2007-12-06

Family

ID=35219398

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020067017946A Ceased KR20070115580A (ko) 2005-03-03 2005-03-03 클로스트리디움 박테리아를 위한 배지 및 클로스트리디움계독소를 얻기 위한 프로세스
KR1020067017947A Ceased KR20070116710A (ko) 2005-03-03 2005-03-03 보툴리눔 독소를 정제하기 위한 동물 산물이 없는 시스템및 프로세스

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020067017947A Ceased KR20070116710A (ko) 2005-03-03 2005-03-03 보툴리눔 독소를 정제하기 위한 동물 산물이 없는 시스템및 프로세스

Country Status (13)

Country Link
US (10) US7354740B2 (https=)
EP (2) EP1853623B1 (https=)
JP (4) JP5006803B2 (https=)
KR (2) KR20070115580A (https=)
CN (2) CN1930186A (https=)
AU (2) AU2005327458B2 (https=)
BR (2) BRPI0508299A (https=)
CA (2) CA2556537A1 (https=)
DK (1) DK1853623T3 (https=)
ES (2) ES2420430T3 (https=)
IL (4) IL177468A (https=)
MX (2) MXPA06009854A (https=)
WO (2) WO2006096163A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160127999A (ko) * 2015-04-28 2016-11-07 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
KR20160127997A (ko) * 2015-04-28 2016-11-07 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
WO2024063404A1 (ko) * 2022-09-23 2024-03-28 (주)제테마 보툴리눔 독소 생산성을 증가시키는 방법

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US7452697B2 (en) 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
US7148041B2 (en) 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US7160699B2 (en) * 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
WO2006096163A1 (en) 2005-03-03 2006-09-14 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
ES2665002T3 (es) * 2007-03-05 2018-04-24 Om Pharma Extracto bacteriano para trastornos respiratorios y procedimiento para su preparación
US8617568B2 (en) 2007-07-10 2013-12-31 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
KR20090120222A (ko) 2008-05-19 2009-11-24 (주)메디톡스 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법
WO2010016901A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type b (150 kd)
WO2010016895A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type b
RS51999B (sr) * 2008-08-28 2012-04-30 Novartis Ag Dobijanje skvalena iz hiperprodukcijskih kvasaca
WO2010051039A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type b
WO2010051038A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type b (150 kd)
KR20110106346A (ko) 2008-12-10 2011-09-28 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
AU2009332947C1 (en) * 2008-12-31 2019-01-03 Revance Therapeutics, Inc. Injectable botulinum toxin formulations
CN101497909B (zh) * 2009-03-05 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 制备抗a型肉毒毒素免疫球蛋白抗体的方法
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
JP2011074025A (ja) * 2009-09-30 2011-04-14 Chemo-Sero-Therapeutic Research Inst ボツリヌス毒素の精製方法
PH12012500549A1 (en) * 2009-10-21 2017-08-23 Revance Therapeutics Inc Methods and systems for purifying non-complexed botulinum neurotoxin
US20130085267A1 (en) 2009-12-18 2013-04-04 Allergan, Inc. Stabilization of Therapeutic Agents to Facilitate Administration
KR101134146B1 (ko) 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
WO2012125948A1 (en) * 2011-03-16 2012-09-20 Biospecifics Technologies Corp. Compositions and methods for producing clostridial collagenases
US20120244188A1 (en) 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251574A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251573A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251575A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
US20120258132A1 (en) 2011-03-29 2012-10-11 Allergan, Inc. Vagal Nerve-Based Disorders
US20120251519A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20120251515A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Cosmesis Disorders
WO2012174123A1 (en) 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
KR101434558B1 (ko) * 2011-07-21 2014-08-27 (주)메디톡스 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여 클로스트리디움 보툴리눔 독소를 생산하는 방법
US20130171122A1 (en) 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
JP2015534814A (ja) * 2012-10-31 2015-12-07 イプセン バイオイノベーション リミテッド 組換えクロストリジウムボツリヌス神経毒
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
JP6363326B2 (ja) * 2013-03-11 2018-07-25 株式会社コーセー 酵母・細菌共通培養方法およびこれに用いる酵母・細菌共通培養培地
KR101339349B1 (ko) * 2013-08-02 2013-12-09 주식회사 대웅 보툴리눔 독소의 제조방법
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
KR101729251B1 (ko) * 2015-04-28 2017-04-21 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
CN108026559A (zh) * 2015-10-21 2018-05-11 诺维信公司 直接接种
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
BR112019004935A2 (pt) 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
CA3060669A1 (en) * 2017-04-28 2018-11-01 Bonti, Inc. Botulinum neurotoxins production methods
EP3675900A4 (en) 2017-08-28 2021-05-05 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
CA3112394A1 (en) 2018-09-13 2020-03-19 Allergan, Inc. Clostridial toxin - hyaluronic acid compositions
US11926853B2 (en) 2018-12-21 2024-03-12 The Research Foundation For Microbial Diseases Of Osaka University Botulinum toxin producing method
KR102197224B1 (ko) * 2019-03-29 2020-12-31 (주)제테마 배지 조성물
KR102516204B1 (ko) * 2019-04-15 2023-03-30 (주)제테마 보툴리눔 독소의 정제방법
KR102447441B1 (ko) 2019-04-15 2022-09-27 (주)제테마 보툴리눔 독소의 정제방법
US10851363B1 (en) * 2019-05-22 2020-12-01 Boke Zhang Multilayer nano-cell containing biomolecules
KR102287437B1 (ko) * 2019-08-14 2021-08-09 주식회사 프로톡스 보툴리눔 독소의 제조방법
TWI854077B (zh) * 2019-12-20 2024-09-01 瑞士商葛德瑪控股公司 生產肉毒桿菌毒素的方法
BR112022019841A2 (pt) 2020-04-09 2022-12-06 Cytomx Therapeutics Inc Composições contendo anticorpos ativáveis
KR102724650B1 (ko) * 2021-07-05 2024-11-01 주식회사 파마리서치바이오 클로스트리디움 보툴리눔 독소 복합체 단백질의 정제방법
KR102724651B1 (ko) * 2021-07-08 2024-11-01 주식회사 파마리서치바이오 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법
KR102512757B1 (ko) * 2021-07-22 2023-03-22 (주)이니바이오 정제 수율이 향상된 보툴리눔 독소 복합체 정제방법
KR102427362B1 (ko) * 2021-11-11 2022-08-01 (주)이니바이오 보툴리눔 독소 제제의 건조 공정
US20250295741A1 (en) 2022-11-07 2025-09-25 Allergan, Inc. Prevention of post-operative atrial fibrillation with a botulinum toxin
KR102890480B1 (ko) 2022-11-08 2025-11-25 (주)제테마 보툴리눔 독소의 정제방법
CH720444A2 (de) 2023-01-20 2024-07-31 Abbvie Inc Clostridium botulinum serotyp a neurotoxin (bont/a)- sequenzvarianten
CH720447A2 (de) * 2023-01-20 2024-07-31 Abbvie Inc Zusammensetzungen von clostridium botulinum neurotoxin serotyp a
CN121358856A (zh) * 2023-03-16 2026-01-16 株式会社大熊 使用多模式色谱法纯化肉毒毒素的改进方法
EP4438716A1 (en) 2023-03-28 2024-10-02 Basf Se Improving microbial activity
WO2025064729A1 (en) 2023-09-19 2025-03-27 Revance Therapeutics, Inc. Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance
KR20250065972A (ko) * 2023-11-06 2025-05-13 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
DE102025101336A1 (de) * 2024-01-19 2025-07-24 Abbvie Inc. Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401683A (en) 1981-07-06 1983-08-30 Fmc Corporation Carbohydrate food products resistant to Clostridium botulinum and the formation of enterotoxin
HK1003981A1 (en) 1989-01-27 1998-11-13 Immunolytics, Inc. Composition and method for treating benign prostatic hypertrophy
US5314822A (en) 1992-10-15 1994-05-24 Merck & Co., Inc. Method of clonal growth of Streptococcus pneumoniae
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
PT1086702E (pt) 1994-05-09 2005-08-31 William J Binder Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca
WO1996005222A1 (en) 1994-08-08 1996-02-22 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
IL118201A (en) * 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
US5861431A (en) 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
ATE372376T1 (de) 1997-05-28 2007-09-15 Novartis Vaccines & Diagnostic Kulturmedium mit sojabohnenextrakt als aminosäuren-quelle und ohne proteinkomplexe tierischen ursprungs
EP1011695B2 (en) 1997-07-15 2009-11-04 The Regents of the University of Colorado Use of neurotoxin therapy for treatment of prostate disorders
US7470431B2 (en) 1997-07-15 2008-12-30 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
US7455845B2 (en) 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US5973341A (en) 1998-12-14 1999-10-26 Philips Electronics North America Corporation Lateral thin-film silicon-on-insulator (SOI) JFET device
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6558926B1 (en) * 1999-07-16 2003-05-06 Massachusetts Institute Of Technology Method for production of tetanus toxin using media substantially free of animal products
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
AU1571801A (en) 1999-11-12 2001-05-30 Eli Lilly And Company Improved fermentation process
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US20030212021A1 (en) 2001-01-25 2003-11-13 Frost Gregory I. Myeloid colony stimulating factor and uses thereof
DE10004024A1 (de) * 2000-01-31 2001-08-02 Guenther Bebenroth Schaltungsanordnung zum Betreiben von Leuchtdioden
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
ATE519494T1 (de) * 2000-02-08 2011-08-15 Allergan Inc Pharmazeutische zusammensetzungen mit botulinum- toxin
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
WO2002026240A2 (en) 2000-09-26 2002-04-04 Sidney Kimmel Cancer Center Inhibition of antigen presentation with poorly catabolized polymers
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
JP2003009897A (ja) * 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
GB0120698D0 (en) * 2001-08-24 2001-10-17 Isis Innovations Ltd Fuel cell
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US20040067235A1 (en) 2002-07-29 2004-04-08 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders
CA2508948A1 (en) 2002-12-16 2004-07-15 Halozyme, Inc. Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
US20040235139A1 (en) * 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7160699B2 (en) 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US7148041B2 (en) * 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US7452697B2 (en) * 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
GB0328060D0 (en) 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
GB2417419A (en) 2004-07-12 2006-03-01 Ipsen Ltd Therapeutic use of Botulinum toxin
WO2006096163A1 (en) 2005-03-03 2006-09-14 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
CA2948238A1 (en) 2005-06-14 2006-12-28 Revance Therapeutics, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
WO2007044809A2 (en) 2005-10-11 2007-04-19 Botulinum Toxin Research Associates, Inc. Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use
US20090304747A1 (en) 2006-05-16 2009-12-10 Mayo Foundation For Medical Education And Research Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders
ES2520765T3 (es) 2007-02-15 2014-11-11 Allergan, Inc. Uso de toxina botulínica para el tratamiento de hiperhidrosis
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160127999A (ko) * 2015-04-28 2016-11-07 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
KR20160127997A (ko) * 2015-04-28 2016-11-07 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
US10465179B2 (en) 2015-04-28 2019-11-05 Daewoong Co., Ltd. Medium composition for preparing botulinum toxin
WO2024063404A1 (ko) * 2022-09-23 2024-03-28 (주)제테마 보툴리눔 독소 생산성을 증가시키는 방법
KR20240041474A (ko) * 2022-09-23 2024-04-01 (주)제테마 보툴리눔 독소 생산성을 증가시키는 방법

Also Published As

Publication number Publication date
IL177467A (en) 2013-09-30
IL177468A0 (en) 2008-03-20
JP2008531047A (ja) 2008-08-14
CA2556537A1 (en) 2006-09-03
CN1930186A (zh) 2007-03-14
EP1853622A1 (en) 2007-11-14
KR20070116710A (ko) 2007-12-11
EP1853623B1 (en) 2013-05-08
US20170342395A1 (en) 2017-11-30
MXPA06009854A (es) 2007-03-29
US7354740B2 (en) 2008-04-08
US20220144887A1 (en) 2022-05-12
US20050238669A1 (en) 2005-10-27
JP2012125251A (ja) 2012-07-05
IL177467A0 (en) 2008-03-20
AU2005327458B2 (en) 2011-12-15
EP1853622B1 (en) 2014-07-16
EP1853623A1 (en) 2007-11-14
JP4913074B2 (ja) 2012-04-11
IL177468A (en) 2015-10-29
US8841110B2 (en) 2014-09-23
IL227909A0 (en) 2013-09-30
MXPA06009853A (es) 2007-03-29
JP2008531046A (ja) 2008-08-14
CA2556796A1 (en) 2006-09-03
US20210024913A1 (en) 2021-01-28
US20210222142A1 (en) 2021-07-22
ES2509872T3 (es) 2014-10-20
JP5006803B2 (ja) 2012-08-22
US20120149089A1 (en) 2012-06-14
BRPI0508374A (pt) 2007-07-31
WO2006096163A1 (en) 2006-09-14
ES2420430T3 (es) 2013-08-23
AU2005327458A1 (en) 2006-10-05
US20130171716A1 (en) 2013-07-04
DK1853623T3 (da) 2013-07-15
US20140178966A1 (en) 2014-06-26
US20210238572A1 (en) 2021-08-05
AU2005327457A1 (en) 2006-10-05
IL241873A0 (en) 2015-11-30
US20210079370A1 (en) 2021-03-18
US8409828B2 (en) 2013-04-02
WO2006096164A1 (en) 2006-09-14
CA2556796C (en) 2018-01-23
CN1946738A (zh) 2007-04-11
JP5518024B2 (ja) 2014-06-11
IL227909A (en) 2016-06-30
AU2005327457A8 (en) 2008-12-18
US9725705B2 (en) 2017-08-08
AU2005327457B2 (en) 2012-08-23
BRPI0508299A (pt) 2007-07-31
JP2012041356A (ja) 2012-03-01

Similar Documents

Publication Publication Date Title
JP5006803B2 (ja) クロストリジウム・バクテリアの培地およびクロストリジウム毒素を得るための方法
KR101100567B1 (ko) 동물 산물이 없는 보툴리눔 독소를 얻기 위한 배지 및 방법
US8012716B2 (en) Media for clostridium bacterium and processes for obtaining a clostridial toxin
AU2013202885B2 (en) Animal product free system and process for purifying a botulinum toxin

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060904

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100119

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110909

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120401

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110909

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I